journal
Journals Best Practice & Research. Clin...

Best Practice & Research. Clinical Endocrinology & Metabolism

https://read.qxmd.com/read/36907788/preface-for-the-2023-beem-issue-on-thyroid-autoimmunity
#1
EDITORIAL
George J Kahaly
No abstract text is available yet for this article.
March 9, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36907786/chemokines-in-thyroid-autoimmunity
#2
REVIEW
Silvia Martina Ferrari, Sabrina Rosaria Paparo, Francesca Ragusa, Giusy Elia, Valeria Mazzi, Armando Patrizio, Marco Ghionzoli, Gilda Varricchi, Marco Centanni, Salvatore Ulisse, Alessandro Antonelli, Poupak Fallahi
The chemokine receptor CXCR3 and its chemokines CXCL9, CXCL10, and CXCL11 are involved in the pathogenesis of autoimmune diseases. Th1 lymphocytes are recruited by Th1 chemokines, secreted by damaged cells. In inflamed tissues, the attracted Th1 lymphocytes induce the IFN-gamma and TNF-alpha release, that stimulates the secretion of Th1 chemokines, initiating and reiterating an amplification feedback loop. Autoimmune thyroid disorders (AITD) are the most recurrent autoimmune diseases, including Graves' disease (GD) and autoimmune thyroiditis, clinically defined by thyrotoxicosis and hypothyroidism, respectively...
March 9, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36907787/sars-cov-2-infection-and-its-effects-on-the-endocrine-system
#3
REVIEW
Charlotte Steenblock, Nicole Toepfner, Felix Beuschlein, Nikolaos Perakakis, Ranjit Mohan Anjana, Viswanathan Mohan, Nitish R Mahapatra, Stefan R Bornstein
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing corona virus disease 2019 (COVID-19) can infect multiple tissues, including endocrine organs, such as the pancreas, adrenal, thyroid, and adipose tissue. The main receptor for SARS-CoV-2, ACE2, is ubiquitously expressed in the cells of the endocrine organs and accordingly, the virus has been detected in various amounts in all endocrine tissues in post-mortem samples from COVID-19 patients. The infection with SARS-CoV-2 may directly lead to organ damage or dysfunction, such as hyperglycaemia or in rare cases, new-onset diabetes...
March 5, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36933997/covid-19-vaccination-and-thyroiditis
#4
REVIEW
Süleyman Nahit Şendur, Seda Hanife Oğuz, Uğur Ünlütürk
At the end of 2019, the world began to fight the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2. Many vaccines have quickly been developed to control the epidemic, and with the widespread use of vaccines globally, several vaccine-related adverse events have been reported. This review mainly focused on COVID-19 vaccination-associated thyroiditis and summarized the current evidence regarding vaccine-induced subacute thyroiditis, silent thyroiditis, Graves' disease, and Graves' orbitopathy...
March 3, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36907785/covid-19-and-metabolic-syndrome
#5
REVIEW
Harsha Dissanayake
Convergence of the two pandemics: metabolic syndrome and COVID-19 over last two years has posed unprecedented challenges to individuals as well as healthcare systems. Epidemiological data suggest a close association between metabolic syndrome and COVID-19 while variety of possible pathogenic connections have been proposed while some have been proven. Despite the evidence of high risk for adverse COVID-19 outcomes in people with metabolic syndrome, little is known about the differences in efficacy and safety among people with metabolic syndrome and without...
March 1, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36878774/pituitary-and-sars-cov-2-an-unremitting-conundrum
#6
REVIEW
Cristina Capatina, Catalina Poiana, Maria Fleseriu
There is increased interest related to the impact of coronavirus disease 19 (COVID-19) on the endocrine system and in particular on the pituitary gland. Over the course of the severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are both acute and delayed effects on the pituitary, related to infection and/or treatment. Hypopituitarism, pituitary apoplexy and hypophysitis have been all reported, as well as arginine vasopressin deficiency (diabetes insipidus) and syndrome of inappropriate antidiuretic hormone secretion...
February 27, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36914551/recent-advances-in-lipidology
#7
EDITORIAL
Kenneth R Feingold, Alan Chait
No abstract text is available yet for this article.
February 24, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36894344/the-bidirectional-interaction-of-covid-19-infections-and-lipoproteins
#8
REVIEW
Kenneth R Feingold
COVID-19 infections decrease total cholesterol, LDL-C, HDL-C, and apolipoprotein A-I, A-II, and B levels while triglyceride levels may be increased or inappropriately normal for the poor nutritional status. The degree of reduction in total cholesterol, LDL-C, HDL-C, and apolipoprotein A-I are predictive of mortality. With recovery lipid/lipoprotein levels return towards pre-infection levels and studies have even suggested an increased risk of dyslipidemia post-COVID-19 infection. The potential mechanisms for these changes in lipid and lipoprotein levels are discussed...
February 24, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36868952/goiters-in-the-renaissance-era-multiple-cases-of-thyroid-autoimmunity-and-iodine-deficiency
#9
REVIEW
Hutan Ashrafian
The Renaissance is recognised as an inflection point in history that led to the dissemination of innovation, science, philosophy, and the arts to spearhead a leap for global civilisation. Many of the greatest outputs from the Renaissance were presented in artwork which was able to champion elements of naturalism and realism, and therefore moved away from preconceived ideas. This included the portrayal of anatomy and pathology with an exactitude previously unseen in art. I note novel identification of goiters in multiple paintings of the foremost Renaissance genius artists and their originating artistic schools, those of Verrocchio, Lippi and Ferrara...
February 15, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36858834/statins-and-diabetes-what-are-the-connections
#10
REVIEW
Naveed Sattar
Randomized trials suggest moderate-intensity statins increase type 2 diabetes risk by around 11% with a potential further 12% moving to high-intensity statins, such that high intensity may increase risk by 20% or more relative to placebo. These data translate into one extra diabetes case per 100-200 statin recipients over 5 years, with ∼10-fold greater benefits on major vascular outcomes. The underlying mechanisms for diabetes harm are not clear but could include modest weight gain (noted in randomized trials), or, speculatively, beta cell harm...
February 15, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36828715/supporting-evidence-for-lipoprotein-a-measurements-in-clinical-practice
#11
REVIEW
Anastasiya Matveyenko, Marianna Pavlyha, Gissette Reyes-Soffer
High levels of lipoprotein(a) [Lp(a)] are causal for development of atherosclerotic cardiovascular disease and highly regulated by genetics. Levels are higher in Blacks compared to Whites, and in women compared to men. Lp(a)'s main protein components are apolipoprotein (apo) (a) and apoB100, the latter being the main component of Low-Density Lipoprotein (LDL) particles. Studies have identified Lp(a) to be associated with inflammatory, coagulation and wound healing pathways. Lack of validated and accepted assays to measure Lp(a), risk cutoff values, guidelines for diagnosis, and targeted therapies have added challenges to the field...
February 11, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36828713/genotype-phenotype-correlations-in-graves-disease
#12
REVIEW
Mikołaj Radziszewski, Aleksander Kuś, Tomasz Bednarczuk
Graves' disease (GD) is a heterogeneous autoimmune disease affecting with varying degrees of severity the thyroid gland, orbital tissues and skin. The pathogenesis of GD involves a complex interplay between multiple genetic, environmental and endogenous factors. Although the genetic predisposition to GD is well established, the significance of genotype-phenotype correlations and the role of epigenetic modifications in the disease pathogenesis remains largely unknown. In this review, we provide an up-to-date overview of genotype-phenotype correlations and summarize possible clinical implications of genetic and epigenetic markers in GD patients...
February 11, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36841747/pathogenic-role-of-th17-cells-in-autoimmune-thyroid-disease-and-their-underlying-mechanisms
#13
REVIEW
Yi Wang, Sijie Fang, Huifang Zhou
Autoimmune thyroid disease, encompassing Graves' disease and Hashimoto's thyroiditis, has a very complex etiology. Pathogenesis of the disease involves both genetic susceptibility and environmental triggers. Traditionally, imbalance of T helper cell 1 and 2 was thought to result in the immune disorders in Graves' disease and Hashimoto's thyroiditis. However, increasing evidence recently revealed the important role of T helper 17 cell and its relative cellular and secretory components in the pathogenesis and progression of autoimmune thyroid disease...
February 8, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36801129/micrornas-in-autoimmune-thyroid-diseases-and-their-role-as-biomarkers
#14
REVIEW
Rebeca Martínez-Hernández, Mónica Marazuela
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at the posttranscriptional level. They are emerging as potential biomarkers and as therapeutic targets for several diseases including autoimmune thyroid diseases (AITD). They control a wide range of biological phenomena, including immune activation, apoptosis, differentiation and development, proliferation and metabolism. This function makes miRNAs attractive as disease biomarker candidates or even as therapeutic agents. Because of their stability and reproducibility circulating miRNAs have been an interesting area of research in many diseases, and studies describing their role in the immune response and in autoimmune diseases have progressively developed...
February 8, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36828714/bioassays-for-thyrotropin-receptor-autoantibodies
#15
REVIEW
Paul D Olivo
Bioassays using animal models were essential tools in the discovery of thyrotropin and in enhancing our understanding of the physiology of the pituitary-thyroid axis. These same bioassays were also instrumental in the discovery of autoantibodies to the thyrotropin receptor (TSH-R-Ab) and in identifying their role in the pathophysiology of Graves' disease. The development of cell-based bioassays led to further advances in our knowledge of the functional activity of TSH-R-Ab and to the discovery that TSH-R-Ab can be either thyroid-stimulating or thyroid blocking, and that they occur in other types of autoimmune thyroid diseases (AITD) besides Graves' disease...
February 5, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36813660/covid-induced-thyroid-autoimmunity
#16
REVIEW
Alessandro Brancatella, Nicola Viola, Ferruccio Santini, Francesco Latrofa
Breakdown of self-tolerance to thyroid antigens (thyroperoxidase, thyroglobulin and the thyrotropin-receptor) is the driver of thyroid autoimmunity. It has been suggested that infectious disease might trigger autoimmune thyroid disease (AITD). Involvement of the thyroid has been reported during severe acute respiratory syndrome virus 2 (SARS-CoV-2) infection, in the form of subacute thyroiditis in subjects with mild coronavirus disease 19 disease (COVID-19) and of painless, destructive thyroiditis in hospitalized patients with severe infection...
February 5, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36732089/quality-of-life-in-thyroid-cancer
#17
REVIEW
Torquil Watt, Thea Christoffersen, Mathilde Borring Brogaard, Jakob Bue Bjorner, Jens Bentzen, Christoffer Holst Hahn, Birte Nygaard, Ulla Feldt-Rasmussen
To explore the impact of differentiated thyroid cancer (DTC) on quality of life (QoL) a clinical analytical framework was developed. Based on the clinical analytical framework, a systematic literature search was performed to identify studies applying patient-reported outcomes (PRO) instruments among patients with DTC. Subsequently, the scope was narrowed down to studies comparing scores on the Medical Outcomes Study (MOS) Short form 36 (SF-36) to a reference population (clinical interpretability criterion)...
January 14, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/35691860/molecular-testing-in-thyroid-cancer-diagnosis-and-management
#18
REVIEW
Jennifer A Sipos, Matthew D Ringel
Molecular diagnostic testing has had a profound impact on the diagnosis and management of thyroid nodules and thyroid cancer. Based on the tremendous expansion of knowledge of the genomic landscape of thyroid cancer over the past few decades, tests have been developed, analyzed, modified, and implemented into clinical practice. Genomic testing of thyroid nodules to improve preoperative diagnosis has become an important component supporting decision-making in clinical care, reducing the need for diagnostic surgeries and improving accuracy of cancer risk assessment...
January 2023: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36511278/innovative-tumour-targeting-therapeutics-in-cushing-s-disease
#19
REVIEW
Vivian von Selzam, Marily Theodoropoulou
Cushing's disease (CD) is the most frequent form of endogenous hypercortisolism. Management of this devastating condition relies on pituitary surgery, while effective pharmacological treatment mainly focus on periphery targeting pharmaceuticals. Approved tumour-targeting drugs are limited to dopamine agonists and somatostatin analogues with frequently low efficacy and substantial side effects. Discoveries on the genetics and pathophysiology of corticotroph tumorigenesis brought forward new potential pharmacological targets...
December 2022: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/36460564/pituitary-neuroendocrine-tumors-from-old-treatments-to-innovations-from-efficacy-to-tolerance-from-benignity-to-carcinomas-where-do-we-stand-now
#20
EDITORIAL
Frederic Castinetti, Gerald Raverot
No abstract text is available yet for this article.
December 2022: Best Practice & Research. Clinical Endocrinology & Metabolism
journal
journal
39740
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.